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Resumo 
 Os microRNAs (miRNAs) têm-se revelado como mediadores cruciais da regulação genética 
em diferentes tipos de células. Há evidências de que subconjuntos específicos de miRNAs 
desempenham um papel proeminente no sistema nervoso, tanto no seu desenvolvimento como em 
doenças neurodegenerativas. Este estudo teve como objectivo elucidar o papel dos microRNAs com a 
morte selectiva de neurónios  motores, característica da esclerose lateral amiotrófica (ALS). 
 Escolheu-se um estágio pré-sintomático pois os níveis dos miRNAs são alterados como 
consequência secundária dos processos de morte celular desencadeados pela doença. Usou-se a técnica 
de microdissecção e captura a laser (LCM) para estudar perfis de miRNAs em neurónios motores de 
espinal medula de ratos SOD1
G93A
, o modelo melhor caracterizado de ALS. Num trabalho preliminar, 
utilizando chips de miRNA específicos foram identificados dois miRNAs consideravelmente sobre-
regulados antes do início da doença. Neste estudo obteve-se RNA de elevada qualidade a partir de 
células capturadas por LCM, o que consistiu num importante avanço no sentido da obtenção de 
resultados significativos da expressão miRNAs em aplicações posteriores. 
 A obtenção de quantidade suficiente de material de partida utilizando LCM para aplicações 
posteriores, ainda é um desafio, apesar desta tecnologia se ter tornado cada vez mais sofisticada. A 
combinação desta técnica optimizada com microarrays, seguida de validação por RT-qPCR pode 
elucidar o papel dos microRNAs na neurodegeneração dos neurónios motores em ALS. 
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Abstract 
 MicroRNAs (miRNAs) are emerging as a primary mediator of gene regulation in many 
different cell types. There is increasing evidence that specific subsets of miRNA play a prominent role 
in the nervous system, both in development and in specific neurodegenerative diseases. This study 
aims to elucidate the role of microRNA in selective motor neuron death that is the hallmark of 
amyotrophic Lateral sclerosis (ALS).  
 Pre-symptomatic time-point was chosen since the levels of miRNAs are highly likely to be 
altered as a secondary consequence of cell injury and death in ALS. Laser capture microdissection 
(LCM) was used to study miRNA profiles in motor neurons of spinal cord tissue from SOD1
G93A
 mice, 
the best characterized model of ALS.  In preliminary work, using miRNA specific chips we have 
identified 2 miRNAs which are dramatically upregulated before disease onset. In this study, high RNA 
quality was achieved from laser captured cells, which consist in a major advance towards obtaining 
meaningful results of these miRNAs expression in downstream applications.  
 Despite LCM technology has become increasingly sophisticated; rapidly obtaining enough 
amount of starting material for downstream applications is still extremely challenging. The 
combination of this optimized technique with microarrays, followed by RT-qPCR may provide 
insights into potential contribution of microRNAs to progression of neurodegeneration of motor 
neurons in ALS. 
 
 
Keywords 
Amyotrophic Lateral sclerosis (ALS); Laser capture microdissection (LCM); microRNAs (miRNAs); 
RT-qPCR; neurodegeneration; RNA quality 
 
 
 
 
 
 x 
 
 
 xi 
Table of Contents 
Acknowledgements ............................................................................................................ v 
Resumo ................................................................................................................................ vii 
Abstract ................................................................................................................................. ix 
List of figures ...................................................................................................................... xv 
List of tables..................................................................................................................... xvii 
List of Abbreviations and Acronyms ........................................................................ xix 
1. Introduction ..................................................................................................................... 1 
1.1. Amyotrophic lateral sclerosis (ALS) ............................................................................. 1 
1.2. SOD1 mutations and neurototoxicity ........................................................................... 3 
1.3. ALS disease models ............................................................................................................. 4 
1.3.1. SOD1 mouse models .................................................................................................................. 4 
1.3.2. Transgenic SOD1G93A mice ...................................................................................................... 5 
1.4. Pathogenic mechanisms of ALS ....................................................................................... 7 
1.4.1. Glutamate-induced Excitotoxicity ....................................................................................... 8 
1.4.2. Oxidative stress and Mitochondrial dysfunction .......................................................... 8 
1.4.3. Protein misfolding and aggregation ................................................................................... 9 
1.5. The potential role of MicroRNAs in ALS .................................................................... 10 
1.5.1. miRNAs Biogenesis and target- Gene Silencing .......................................................... 11 
1.5.2. Potential role of MicroRNAs in neurodegeneration .................................................. 13 
1.5.3. Searching for microRNAs implicated in ALS ................................................................ 14 
1.6. Background ......................................................................................................................... 16 
1.7. Aims of this thesis ............................................................................................................. 16 
2. Materials and Methods .............................................................................................. 17 
2.1. Animals ................................................................................................................................. 17 
2.1.1. SOD1G93A transgenic mice..................................................................................................... 17 
 xii 
2.1.2. Genotyping ................................................................................................................................. 17 
2.1.3. Lumbar spinal cord dissection ........................................................................................... 20 
2.2. Histology .............................................................................................................................. 21 
2.2.1. Cryostat sectioning ................................................................................................................. 21 
2.2.2. Fixation and Hydration ......................................................................................................... 21 
2.2.3. Cresyl violet staining .............................................................................................................. 21 
2.2.4. Washing and Dehydration ................................................................................................... 21 
2.3. Laser Capture Microdissection (LCM) ....................................................................... 22 
2.4. miRNA/RNA extraction ................................................................................................... 23 
2.5. RNA quantification and quality control .................................................................... 23 
2.6. Reverse transcription and quantitative PCR (RT-qPCR) .................................... 24 
2.6.1. RT-qPCR TaqMan MicroRNA Assays ............................................................................... 25 
2.6.2. RT-qPCR Megaplex TM Pool with cDNA preamplification step .............................. 28 
3. Results ............................................................................................................................. 33 
3.1. Genotyping of WT and SOD1G93A Mice Littermates ............................................... 33 
3.2. Motor Neurons Isolation by LCM ................................................................................. 34 
3.3. RNA Quantity and Quality Assessment...................................................................... 36 
3.3.1. Quantity of total RNA was accurately determined by RiboGreen Assay .......... 36 
3.3.2. Quality of total RNA improves substantially with RNase Inhibitor .................... 38 
3.4. Expression profiling of microRNA using real-time quantitative PCR ............ 42 
4. Discussion ...................................................................................................................... 45 
4.1. Laser Capture Microdissection: Advantages/ disadvantages and effect on quality 
and yield of RNA ......................................................................................................................... 45 
4.2. Effect of RNase Inhibitor on RNA integrity assessed by Bioanalyser ............. 47 
4.3. RNA quality and yield impact and real time RT-qPCR microRNA analysis .. 48 
4.4. Concluding remarks and Future Prospects ............................................................. 50 
5. References ..................................................................................................................... 53 
 xiii 
Supplementary data ....................................................................................................... 63 
Supplement  S1: TaqMan MicroRNA Arrays .................................................................... 63 
 
 xiv 
 xv 
List of figures  
Figure 1.1 Incidence rate of amyotrophic lateral sclerosis in the General Practice Research Database 
(GPRD), by age and sex, 1990–2005. (p2) 
Figure 1.2 Time course of clinical and neuropathological events in high copy number transgenic 
SOD1G93A mice. (p6) 
Figure 1.3 Proposed mechanisms of toxicity in SOD1-mediated ALS. (p7) 
Figure 1.4 Biogenesis and mode of action of miRNAs in mammalian cells. (p12) 
Figure 1.5 Proposed Mechanisms by which miRNAs could influence neurodegeneration. (p13) 
Figure 2.1 Spinal cord removal method from vertebral column of presymptomatic transgenic 
SOD1
G93A
 and WT mice. (p20) 
Figure 2.2 RNA quality of extracted total RNA measured using Agilent 2100 bioanalyzer. (p24) 
Figure 2.3 Schematic description of RT–PCR TaqMan® MicroRNA Assay chemistry including two 
steps. (p26) 
Figure 3.1 Ethidium bromide–stained 1.5% agarose gel for genotyping of 5 samples from mice 
littermates. (p33) 
Figure 3.2 Laser Capture Microdissection (LCM) of motor neurons from 1% cresyl violet stained 
lumbar spinal cord (SC) sections of 40-day-old SOD1G93A (A, B, C, D) and WT (E, F, G, H) mice.  
(p35) 
Figure 3.3 Standard curve for RNA concentration using RiboGreen assay. (p37) 
Figure 3.4 Preservation of RNA integrity from LCM single cells, by addition of RNase Inhibitor and 
staining optimization. (p38) 
Figure 3.5 Quality of extracted RNA from 600 motor neurons collected by LCM samples was 
analysed using Agilent RNA 6000 Pico chip, on a 2100 Bioanalyser. (p40) 
Figure 3.6 Quality of extracted RNA from 3 spinal cord sections from WT (A,B) and SOD1
G93A
 (C, 
D) mice was analysed using Agilent RNA 6000 Pico chip on a 2100 Bioanalyser. (p41) 
 
 xvi 
Figure 3.7 Standard curve analysis depicting perfect linearity and correlation between input quantity 
(40-0.4 ng/µl) and measured Threshold Cycle (CT) value for four different miRNAs (miR-182, miR-
34c, miR-234 and miR-202). (p43) 
Figure S1 TaqMan Rodent MicroRNA Array cards. (p64 and 65) 
 xvii 
List of tables 
Table 1.1 Transgenic mutant SOD1 mouse models.(p5) 
Table 2.1 Multiplex PCR Master mix reaction components for a final reaction volume of 25 μl used 
for genotyping SOD1 G93A mice and WT littermates. (p18) 
Table 2.2 PCR primer pairs of transgene and internal positive control used for genotyping SOD1 
G93A mice and WT littermates. (p19) 
Table 2.3 Cycling conditions used for genotyping SOD1 G93A mice and WT littermates. (p19) 
Table 2.4 RT reaction master mix components in a final volume of 15 μl  including 7 μl master mix, 3 
μl of each primer and 5 μl total RNA. (p25) 
Table 2.5 Cycling conditions to perform RT reaction followed by qPCR. (p26) 
Table 2.6 Real-time PCR reaction mixture components. (p27) 
Table 2.7 Parameter values used to program the thermal cycler to perform real-time PCR. (p28) 
Table 2.8 RT reaction Mix components in final reaction volume of 7.5 μl. (p29) 
Table 2.9 Cycling conditions used for Megaplex TM RT reaction. (p29) 
Table 2.10 PreAmp Reaction Mix Components. (p30) 
Table 2.11 PreAmp Reaction Mix Cycling conditions. (p30) 
Table 3.1 RFU corrected values and RNA concentration of RNA standard sample in a final volume 
assay of 200μl. (p36) 
Table 3.2 RFU corrected values and RNA concentration of RNA ([RNAinitial]=5.7 ng/μl diluted to 
1ng/μl) sample in a final volume assay 200μl. (p37) 
Table S1 TaqMan MicroRNA Arrays (p63) 
 
 
 xviii 
 xix 
List of Abbreviations and Acronyms 
  
ABP  Amyloid-ß peptide 
AD  Alzeimer Disease 
ALS  Amyotrophic Lateral Sclerosis 
ATF6   Activating transcription factor 6 
BiPs  Binding immunoglobulin Proteins 
EAATs  Excitatory Aminoacid Transporters  
ER  Endoplasmic Reticulum 
ERAD  ER-associated degradation 
FALS  Familial Amyotrophic Lateral Sclerosis 
FGF20  Fibroblast Growth Factor 20 
FGFBP1 Fribroblast Growth Factor Binding Protein 1 
FUS /TLS Fused in Sarcoma /Translated in Liposarcoma Protein 
GLT1  Glutamate Transporter 1 
HD  Huntington’s Diease 
HDAC4 Histones Deacetylase 4 
IPC  Insolube Protein Complexes 
IRE1  Inositol-requiring enzyme 1 
KBBP  Appa B motif- binding phosphoprotein 
LCM  Laser Capture Microdissection 
miRNA  microRNA 
 xx 
MND  Motor neuron disease 
NFQ  Nonfluorescent quencher 
NMJ  Neuromuscular Junction 
NMJ  Neuromuscular junction 
OCT  Optimal cutting temperature compound  
PBS  Phosphate buffered saline 
PD  Parkison Disease 
PERK  Protein kinase RNA-like endoplasmic reticulum kinase 
Pre-miRNA Precursor-microRNA 
Pri-miRNA Primary-microRNA 
qPCR  Quantitative PCR 
REST  RE1 silencing transcription factor 
RISC  RNA-induced silencing complex 
RT  Reverse Transcription 
SALS  Sporadic Amyotrophic Lateral Sclerosis 
SC  Spinal Cord 
SMA  Spinal Muscular Atrophy  
SMN  Spinal Motor Neuron 
SOD1  Superoxide dismutase 1 
TDP-43 TAR DNA-binding protein 43 
UTR  Untranslated region 
WT  Wild- Type 
 1 
1. Introduction 
1.1. Amyotrophic lateral sclerosis  
 Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by 
selective degeneration and loss of upper and lower motor neurons (MNs) that leads to progressive 
weakness of limbs, paralysis and ultimately to death.  
 The disease was first described in 1869 by the French neurologist Jean-Martin Charcot. 
Although exciting new insights regarding the potential mechanisms that underlie the 
neurodegeneration have emerged in recent years, there are still no effective treatments for ALS. 
 Characteristic clinical manifestations of ALS include spasticity and hyperreflexia due to the 
dysfunction of upper MNs, and generalized weakness, muscle atrophy, and paralysis as a result of 
lower MN damage. Certain populations of MNs, eg; those serving oculomotor function, are relatively, 
though can be involved in later disease in patients with ALS (Sharma R. et al, 2011). The disease 
symptoms progress rapidly leading to death, usually due to respiratory failure, on average within 2-3 
years of onset.  
 ALS is the third most common adult neurodegenerative disease (after Alzheimer’d disease 
and Parkinson’s disease), with an annual incidence of 2 per 100,000 population and a prevalence of 5 
to 7 per 100,000. The estimated lifetime risk of being diagnosed with ALS is 1 in 400-700 (Andersen 
P.M., 2006). There are approximately 4-5000 patients with ALS in the United Kingdom and 25,000 
patients with ALS in the USA. Moreover, population-based studies have found that MND incidence is 
higher in men than women, with an incidence for both sexes which peaks at age 75–79 (Alonso A. et 
al, 2009). Typical age onset of sporadic ALS been reported between 60 and 80 years with rapid 
symptom progression to death, but juvenile ALS cases, which are typically inherited, with slow 
symptom progression have also been described (Butterfield R. J. et al, 2009).  
 The majority of ALS cases (80- 90%) correspond to a sporadic form of the disease (SALS) in 
which there is no apparent genetic linkage and the primary causes remain unknown. About 5-10% of 
ALS cases are reported as familial (FALS) in which the disease is inherited in a mendelian autosomal 
dominant mode with high penetrance (Cleveland D. W. and Rothstein J. D., 2001). 
 However, the distinction between FALS and SALS cases is less clear than previously thought 
and the genetic contribution to ALS is likely to be higher than 5-10%.  Apparently sporadic ALS 
could be due to autosomal dominant inheritance and low penetrance, autosomal recessive inheritance, 
compound heterozygosity or oligo-genetic inheritance. More than 20% of FALS cases and 1-7% of all 
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SALS are related with mutations in the Cu/Zn Superoxide dismutase 1(SOD1) gene (Valdmanis P.N. 
et al, 2009). 
 Other genes implicated in FALS include Fused in sarcoma protein (FUS), TAR-DNA binding 
protein of molecular weight 43 kDa (TDP43). Mutations in FUS and TDP43 correspond to 
approximately 5% of all FALS cases each (Kwiatkowski et al., 2009, Kabashi et al., 2008).  In 
addition, mutations in other genes, including ALS2, SETX, SPG11, VAPB, ANG, and OPTN have 
also been associated with ALS but account for less than 5% of FALS, and often occur in patients with 
atypical phenotypes different from sporadic ALS (Nishimura et al., 2004; Pasinelli P. and Brown 
R.H., 2006; Orlacchio A. et al, 2010; Maruyama et al., 2010). 
 Since FALS patients are indistinguishable clinically from SALS patients, new insights into the 
causes and pathogenic mechanisms of FALS might contribute to develop effective therapies also for 
the much common form of the disease, sporadic ALS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Incidence rate of amyotrophic lateral sclerosis in the General Practice Research Database 
(GPRD), by age and sex, 1990–2005. (Alonso A. et al, 2009) 
 
 However, significant clinical heterogeneity has been reported in patients with ALS. Patients 
carrying the same mutations in TARDBP and SOD1 genes have shown different clinical 
manifestations such as age at onset and sites of onset (Piaceri I. et al, 2011). This suggests that 
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epistatic or epigenetic mechanisms involving unknown other genes might contribute to the clinical 
manifestations of the disease. Therefore, an important step to clarify the causes of ALS is to 
understand the clinical heterogeneity observed.  
 ALS is a complex multifactorial disease in which the clinical manifestations are influenced by 
a combination of both genetic and environmental factors. For these reasons, the pathogenic 
mechanisms inherent in ALS are not fully elucidated yet and further research is needed in this field. 
 
1.2. SOD1 mutations and neurototoxicity 
 The first major genetic contribution to the understanding of ALS came with the discovery of 
mutations in the SOD1 gene on chromosome 21q22.11 (Rosen, D. R. et al). The SOD1 gene is 
composed of five exons and encodes the antioxidant enzyme Cu/Zn SOD1 that converts superoxide 
radicals, generated by mitochondrial oxidative phosphorylation, to water and hydrogen peroxide. The 
cytoplasmic Cu/Zn SOD1 protein is ubiquitously expressed and highly conserved. The majority of 
SOD1 mutations identified are missense substitutions observed at almost any position throughout the 
gene. In exon 4 and 5 of the gene, frameshift deletions and insertions have also been reported (Shaw 
B.F. and Valentine J.S., 2007).  
 It has been reported that SOD1- mediated toxicity in ALS is not due to loss function but to a 
gain of function. In fact, transgenic mice overexpressing the human mutant SOD1 develop the disease 
but SOD1 knockout mice do not show ALS symptoms (Gurney et al., 1994; Reaume et al., 1996).  
Moreover, it has been reported that some SOD1 mutants retain full catalytic activity and there is no 
correlation between the levels of enzymatic activity and the disease phenotype (Shaw B.F. and 
Valentine J.S., 2007). This suggests that SOD1 mutations possibly result in the acquisition of toxic 
properties of mutant SOD1, causing motor neuron degeneration. 
 Among the gene mutations associated with ALS identified so far, only SOD1 mutations have 
been observed in a substantial number of ALS cases (>20% of autosomal dominant FALS cases). 
Therefore, clarifying the potential pathogenic mechanisms linked with SOD1 mutations is crucial to 
understand the causes of ALS. 
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1.3. ALS disease models 
1.3.1. SOD1 mouse models 
 Over the years, several animal models have been used to study the selective motor neuron 
death, the hallmark of ALS. Many models were created in order to understand the SOD1-mediated 
toxicity in mice, rats, zebrafish, Drosophila melanogaster and Caenorhabditis elegans. 
 The first animal model of ALS was created in the mouse transgenically expressing the human 
SOD1 gene that encodes the G93A mutation from the human SOD1 promoter (Gurney et al, 1994). 
For more than a decade, the mutant SOD1 mouse has been the best model to study the mechanisms 
underlying ALS pathogenesis. However, this model has not lead yet to a key step forward in ALS 
therapeutics. Therefore, ALS research directions include generating new mouse models of the disease 
based on other gene mutations, such as the recent mutations discovered in the genes encoding TDP-43 
and FUS/TLS. Despite these attempts to create better mouse models based on these genes, mutant 
SOD1 mice models remain the best models presently available to study the pathogenesis of ALS and 
to test new therapies. 
 Currently, there are 12 SOD1 human ALS mutations expressed in mice (table 2). Besides the 
original SOD1 
G93A
 mice, other transgenic mice were created, overexpressing human SOD1 with other 
mutations such as G37R, G85R, G86R and D90A. These 12 mutations include 9 missense and 3 C-
terminally truncated variants (SOD1
L126X
, SOD1
L126delTT
 and SOD1
G127X
). 
 The SOD1
G93A
 mice are the most frequently used transgenic mice models in ALS research, 
although many studies have also been conducted using the SOD1G37R, SOD1G85R and SOD1G86R 
transgenic mouse models (Bruijn and Cleveland, 1996). While the SOD1G93A and SOD1G37R 
mutants are stable, active and highly expressed, the SOD1
G85R
 mutant proteins are unstable and lower 
expressed  (Turner and Talbot, 2008). 
 The phenotypes of mutant SOD1 mouse models may depend on the transgene expression level 
and mutation type. It was described that mice expressing higher amounts of the SOD1
G93A
 transgene 
develop the disease earlier than the mice expressing lower amounts of the transgene. 
 Moreover, transgenic SOD1
A4V
 mice showed symptoms in the later stages of the disease (>85 
weeks) contrary to what as observed in humans, where the disease is rapidly progressive, likely due to 
low transgene expression level. However, double transgenic mice expressing the SOD1
A4V
 transgene 
and overexpressing wild-type SOD1 develop the earliest symptoms of ALS (35 weeks) (Deng et al. 
2006).  
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 Since most mouse SOD1 transgenics recreate many features of ALS seen in human patients, 
they have been crucial in ALS research.  The SOD1
G93A
 mouse is so far the main animal model for 
ALS and has provided a relevant basis for study potential mechanisms of ALS. 
 
Table 1.1 Transgenic mutant SOD1 mouse models. Adapted from Joyce et al, 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
   
nd not described,  
dl G1 del—low copy,  
a Double transgenic with SOD1WT 
b Mouse transgene 
 
1.3.2. Transgenic SOD1G93A mice 
 The transgenic mice are generated using a transgenic construct containing 12-15 kb human 
genomic fragments encoding SOD1.  The transgene is ubiquitously expressed under control of the 
human or mouse SOD1 gene promoter at much higher levels than the level of endogenous SOD1, due 
to insertion of multiple copies of the transgene into the mouse genome. The G93A mouse used in this 
work contains approximately 20 copies of the transgene, expresses protein at 6-10 fold higher levels 
than endogenous and has 11-fold higher SOD1 activity. The mutations induce fatal symptoms 
characteristic of ALS with onset at 3-4 months and death within 1-2 months of onset (Turner and 
Talbot, 2008). 
 These mice exhibit hindlimb tremor and paresis around 90 days that coincides with crucial 
cellular changes such as axonal degeneration in motor neurons as well as astrocytes and microglia 
activation (Gurney et al. 1994; Chiu et al. 1995; Hall et al., 1998).  As the disease progresses, mice 
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show severe symptoms such as hyper-reflexia and paralysis. The progressive motor neurons loss in the 
lumbar spinal cord leads to death around 120 days.  
 The motor neuron loss begins at the distal axon and proceeds to the later proximal axonal loss 
around 80 days leading to a evident lower motor neuron death at 100 days, showing a "dying back" 
pattern (Fischer et al., 2004). In addition, ALS does not only cause the loss of lower motor neurons in 
transgenic SOD1
G93A
 mice but also loss of descending cortical and bulbar neurons (Zang and Cheema, 
2002). 
 Several molecular mechanisms may underlie the phenotype including Golgi apparatus 
fragmentation, mitochondrial vacuolization, and mutant SOD1 aggregation into insoluble protein 
complexes (IPC) inclusion bodies that lead to endoplasmic reticulum (ER) stress, contributing to 
motor neuron degeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Time course of clinical and neuropathological events in high copy number transgenic 
SOD1G93A mice. Mice develop hindlimb tremor, weakness and locomotor deficits at about 3 months, 
which is preceded by distal synaptic and axonal degeneration. This progresses into fatal paralysis 
about 1 month later concomitant with spinal motor neuron loss and reactive gliosis. A sequence of 
mutant SOD1 aggregation into insoluble protein complexes (IPC), inclusion bodies modified by the 
ubiquitin-proteasome system (UPS) and subcellular degeneration in motor neurons may underlie the 
phenotype (Turner and Talbot, 2008). 
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 The advantages of this model include predictable disease progression and the fact that it 
replicates many of the clinical, cellular and molecular features of ALS observed in human patients 
with ALS. Therefore, this transgenic mouse model has been a great contribution to understanding the 
pathogenic mechanisms of ALS. 
1.4. Pathogenic mechanisms of ALS 
 Over the years, various pathogenic mechanisms have been proposed to explain selective motor 
neuron degeneration in ALS, including glutamate - induced excitotoxicity, oxidative stress, protein 
aggregation, mitochondrial dysfunction, deficits in neurotrophic growth factors, astrogliosis, 
microgliosis and inflammation.  
 
Figure 1.3 Proposed mechanisms of toxicity in SOD1-mediated ALS. (A) Excitotoxicity; (B) ER 
stress (C) Proteasome inhibition (D) Mitochondrial dysfunction (E) Toxic extracellular mutant SOD1. 
(F) Superoxide production. (G) Altered axonal transport (H) Synaptic vesicle defects (I) Loss of tight 
junction proteins. Adapted from Ilieva H. et al 2009. 
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 The transgenic mice expressing mutant SOD1 have been essential to define the potential 
disease mechanisms and understand how a mutation in SOD1 enzyme, which is ubiquitously 
expressed, could be a primary cause of selective motor neuron death in ALS. 
1.4.1. Glutamate-induced Excitotoxicity 
 Excitotoxic damage is one of the mechanisms that could explain the selectivity of motor 
neuron death and the role of neighbouring non-neuronal cells in ALS.  
 The repetitive stimulation of glutamate receptors occurs due to a failure to rapidly remove 
glutamate from the synaptic cleft by excitatory amino acid transporters (EAATs). It has been reported 
that mutant SOD1 induces oxidative damage to the intracellular C-terminal part of the astroglial 
glutamate transporter EAAT2. This event contributes to a selective loss of EAAT2 transporter in 
astrocytes of motor cortex and spinal cord in sporadic and familial ALS patients (Trotti D. et al, 1999; 
Van Damme P. et al, 2005). In addiction, the transcription of EAAT2 was found reduced in astrocytes 
due to reduced expression of a kB motif binding phosphoprotein (KBBP), which is stimulated by 
neurons and required for GLT1/EAAT2 transcriptional activation (Yang Y. et al, 2009). 
 The hyperactivation of motor neurons by glutamate leads to high calcium influx and 
subsequently to activation of apoptotic pathways, which leads to motor neuron death (Foran E., Trotti 
D., 2009).  
 The intrinsic characteristics of motor neurons, observed in SOD1 mice spinal cord, contribute 
to explain the selective motor neuron death. These characteristics include a decreased of GluR2 
AMPA subunit levels and an increase of GluR3 expression that explain high calcium influx. In 
addiction, motor neurons have low expression of calcium binding proteins that leads to low calcium 
buffering capacity (Tortarolo M. et al, 2006).  
 Excitotoxicity is an interesting mechanism and a potentially druggable target (Bogaert E. et al, 
2010). However, it remains unclear whether these changes represent a primary defect that causes 
motor neuron degeneration, or are a downstream result of other primary ALS pathways. 
 
1.4.2. Oxidative stress and Mitochondrial dysfunction 
 There is substantial evidence suggesting a crucial role for oxidative stress in the pathogenesis 
of ALS. It has been reported that mutations in the SOD1 gene result in an increase in oxidative 
damage, which contributes to activation of apoptotic pathways (Barber S. C. et al, 2006).  
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 The major source of oxidative stress is mitochondria, which play essential roles in ATP 
production, excitotoxicity, cell survival and apoptosis. Morphological and functional defects in 
mitochondria have been observed both in SOD1 mutant mouse models and human patients (Higgins 
C. M., et al, 2003). Mitochondrial dysfunction has been observed presymptomatically not only in 
motor neurons but also in astrocytes, indicating that this mechanism can be a relevant contribution to 
triggering the disease (Damiano et al 2006; Cassina et al, 2008). Mutant SOD1 deposition on the 
mitochondrial membrane leads to decreased activity of respiratory complexes and release of 
cytochrome C in motor neurons, whereas in astrocytes causes nitroxidative stress (Vande V.C. et al, 
2008). The mitochondrial localization of mutant SOD1 increases with the overexpression of copper 
chaperone for SOD1, contributing to neurodegeneration (Son M., et al, 2007).  
 
1.4.3. Protein misfolding and aggregation  
 Similarly to other neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, 
the presence of mutant protein aggregates or inclusions has also been reported in ALS. SOD1 mutant 
protein tends to be misfolded and forms cytoplasmic aggregates that occur early in disease. These 
aggregates have been observed in motor neurons and neighbouring astrocytes in the established ALS 
mouse models  (Bruijn et al. 1998). 
 Several studies have been conducted in order to clarify the mechanisms by which the SOD1 
protein aggregates may contribute to damage the motor neurons and astrocytes. It has been shown that 
the toxicity of aggregates arises from dysfunction of mitochondria, peroxisomes; indution of ER stress 
and inihibition of proteasome-mediated degradation pathway.  
 Mutant SOD1 aggregates were found in ER membranes, where they interact with endoplasmic 
reticulum (ER) proteins inducing ER stress pathways. It has been described that ER binding 
immunoglobulin proteins (BiPs) bind to SOD1 aggregates and act as chaperones that regulate the 
activation of unfolded protein response transducers such as IRE1, PERK, and ATF6 (Kikuchi et al, 
2006).  
 The accumulation of SOD1 aggregates restrain the ER-associated degradation (ERAD) 
pathway responsible for the degradation of misfolded proteins found in the ER. The inhibition of the 
ERAD process is mediated by the binding of mutant SOD1 with derlin-1, a transmembrane ER protein 
that is involved in the transport of misfolded proteins from the ER to the cytosol, where the misfolded 
proteins are degraded by the proteasome. However, the interaction between mutant SOD1 and derlin-1 
was not observed in a presymptomatic stage of the disease, indicating that this event occurs as a result 
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of another unidentified early event (Nishitoh et al, 2008). In contrast, up-regulation of ER stress-
related genes before disease onset was observed in motor neurons in mice expressing mutant SOD1, 
showing that ER stress responses influence the progressive manifestations of the disease (Saxena et 
al., 2009). Moreover, biochemical studies have provided evidence of decreased proteasome activity in 
motor neurons of G93A SOD1 mice spinal cord, showing that UPS impairment may play a role in the 
disease progression (Cheroni et al., 2009). 
 
 
1.5. The potential role of MicroRNAs in ALS  
 The first microRNA (miRNA) gene, lin-4, was discovered in 1993 as a result of a genetic 
screen for mutations in Caenorhabditis elegans (Lee et al, 1993). Since then, many miRNAs have 
been identified in several plants and animals.  
 MicroRNAs are small evolutionarily conserved noncoding RNAs (approximately 22 
nucleotides long) that have emerged as key regulators in the majority of biological processes such as 
cell proliferation, differentiation, metabolism and apoptosis. It has been reported that miRNAs are 
strongly regulated and responsible for the most abundant mode of post-transcriptional regulation of 
diverse downstream targets (Lu et al, 2008). It is estimated that more than 60% of human protein-
coding genes have miRNA target sites in their 3’ untranslated region and are potentially regulated by 
these molecules (Friedman et al, 2009; Sayed D. et al, 2011). Many miRNAs are expressed in the 
nervous system and play an important role in neuronal differentiation, synaptogenesis and plasticity 
(Vo et al, 2010). In recent studies, microRNAs have been shown to have an important role in many 
disorders such as cancer, cardiovascular and neurodegenerative diseases. Therefore, the discovery of 
key miRNAs that target known mediators of neurodegeneration may contribute to finding potential 
therapeutic targets for ALS.  
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1.5.1. miRNAs Biogenesis and target- Gene Silencing  
 
 The majority of miRNAs are localized in intergenic regions, although a minority were found 
in the intronic regions of known genes (Griffiths-Jones et al, 2006). It has been reported that 
intragenic miRNAs are co-transcribed with their host genes while most intergenic miRNAs are 
transcribed from their own RNA polymerase II promoter (Corcoran D.L. et al., 2009). 
 The miRNA gene expression pathway is initiated in the nucleus, where the miRNAs genes are 
transcribed by RNA polymerase II or III into primary miRNA transcripts (pri-miRNA), which can be 
more than 1000 nucleotides in length. The pri-mRNA is cleaved by Drosha RNase III endonuclease to 
a ~70 nt stem loop precursor miRNA pre-miRNA. The resulting pre-miRNA is transported to the 
cytoplasm via Exportin-5. Once in the cytoplasm, the pre-miRNA is processed by a RNase III 
endonuclease (Dicer) which cleaves it to produce a mature double-stranded RNA of 19–23 
nucleotides. One strand of the duplex is degraded, whereas the other strand is the mature microRNA 
that binds to Dicer and Argonaute (Ago) proteins to form RNA-induced silencing complexes (RISCs) 
(Fig.1.4; Hebert and De Strooper, 2009). Consequently, the RISC complex mediates post-
transcriptional gene regulation by binding through imperfect base-pairing interactions with sequences 
in the 3’ UTR of target mRNAs in animals (Nahvi et al, 2009). This leads to a repression of protein 
synthesis or mRNA degradation.  
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Figure 1.4 Biogenesis and mode of action of miRNAs in mammalian cells. Endogenously expressed 
from the genome, miRNA genes are transcribed by DNA polymerase II (or III) to produce long 
(>1000 nucleotides [nt]) primary transcripts (pri-miRs) that resemble in structure classical mRNA 
(mRNA) molecules (i.e. possess a 50 cap and a polyA tail). These transcripts are further processed in 
the nucleus by the Drosha–DGCR8 enzymatic complex to generate a hairpin-like precursor miRNA 
(pre-miRNA). Once exported in the cytoplasm by exportin 5, the 70 nt pre-miRNA is a substrate for 
Dicer, which produces the mature 19–23 nt miRNA molecule (blue). Upon incorporation into the 
RISC complex, composed of argonaute and associated proteins, the miRNA ‘guide’ strand binds the 
30UTR of target mRNA sequences (green) with partial complementarity, which leads to translation 
inhibition (possibly via deadenylation) or degradation. Adapted from Hebert and De Strooper, 2009. 
 
 Several models have been proposed for miRNA-mediated gene regulation, including 
repression of translation at the level of initiation at either the cap recognition stage or the 60S subunit 
joining stage, repression of translation at post-initiation level, proteolytic degradation of nascent 
polypeptides and miRNA mediated deadenylation followed by decapping and degradation of target 
mRNA (Filipowicz W. et al, 2008). However, the exact mechanisms underlying miRNA-mediated 
gene regulation are still not fully understood. 
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1.5.2. Potential role of MicroRNAs in neurodegeneration 
 Several recent studies have reported exciting findings regarding differential expression of 
miRNAs in patients and models of many neurodegenerative disorders. These studies have focused on 
understanding the influence of miRNAs on both neuronal survival and the accumulation of toxic 
proteins that lead to neurodegeneration. Since increasing evidence indicates regulatory feedback loops 
between miRNAs and their targets, it is also relevant to study how these toxic proteins may affect 
miRNA expression. 
 A common feature among many neurodegenerative diseases is the accumulation of mutant 
proteins with toxic properties that contribute to neuronal degeneration. Therefore, two mechanisms 
have been proposed to explain the role of microRNAs in neurodegeneration: reduction or absence of 
the microRNAs and mutation of a miRNA-binding site in the 3’untranslated region of a target mRNA 
(Eacker et al, 2009). These mechanisms would be predicted to prevent miRNA mediated repression 
and lead to an increase of the target toxic proteins or proteins that are involved in the production of 
toxic proteins. The accumulation of toxic proteins is likely to cause neuronal death and also affects the 
expression of miRNAs responsible for the neuronal survival (Figure 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Proposed Mechanisms by which miRNAs could influence neurodegeneration. A) reduction or 
absence of miRNAs. B) mutation of  miRNA-binding site in the 3’untranslated region of a target mRNA. 
Both mechanisms lead to increase of toxic proteins that cause neuronal death and affects the expression of 
unidentified pro-survival miRNAs. Adapted from Eacker et al, 2009.  
  
A                                                                   B 
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 Several miRNA profiling studies have identified differentially expressed miRNAs in 
neurodegenerative diseases, including miR-29a/29b, miR-433, miR-133b and miR-9/9*. For instance, 
a correlation between lower expression of miR-29a/29b and higher expression of BACE1 was found 
in brains of patients with Alzheimer disease (AD), suggesting that miR-29 family might play a role in 
preventing the accumulation of toxic amyloid-ß peptide (APP) (Bettens et al, 2009). An example of a 
miRNA that may be implicated in Parkinson disease (PD) is the miR-433 since a point mutation was 
found in the 3’ UTR of fibroblast growth factor 20 (FGF20) that disrupts the miR-433 binding site 
leading to an increased expression of α-synuclein (Wang et al, 2008). Moreover, a decrease in miR-9 
expression was observed as Huntington’s disease (HD) progresses. It has been described that miR-9 
may regulate the expression of proteins involved in neuronal survival through its interaction with RE1 
silencing transcription factor (REST) and its co-repressor coREST (Packer et al, 2008). 
 
1.5.3. Searching for microRNAs implicated in ALS 
 Despite recent studies providing some insight into how miRNAs may be involved in 
neurodegeneration, there is still very little information about deregulated miRNA expression 
associated with ALS. 
 The FUS/TLS and TARDBP/TDP43 ALS-linked proteins, interact with several proteins that 
are components of Drosha microRNA processing complexes, suggesting that they may be involved in 
the regulation of miRNA expression (Gregory et al, 2004; Ling et al, 2010). 
 Various studies identified several miRNAs specifically expressed in skeletal muscles such as 
miR-1, miR-133, miR-181, miR-214, and miR-206 (van Rooij et al, 2008). A recent study 
investigated whether ALS progression in SOD1 G93A transgenic mice was accompanied by changes 
of miRNA expression in muscle. Williams et al found that from 320 miRNAs tested, the muscle-
specific miR-206 was the most dramatically upregulated. Mice homozygous for the target deletion of 
miR-206 showed normal neuromuscular synapses during development, however SOD1 G93A mice 
with deficiency of miR-206 shown an acceleration of ALS progression. Furthermore, miR-206 was 
shown to contribute to regeneration of neuromuscular synapses through a mechanism that involves 
histone deacetylase 4 (HDAC4), which normally inhibits nerve reinnervation by blocking the 
expression of fibroblast growth factor binding protein 1 (FGFBP1). So, miR-206 affects the activity of 
HDAC4, activating FGFBP1 expression and ensuring neuromuscular junction (NMJ) integrity and 
plasticity. In addition, it was observed that a decrease of miR-206 does not affect the disease onset but 
causes rapid ALS progression leading to atrophy of skeletal muscle, paralysis and death. Therefore, 
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miR-206 may be involved in a compensatory response to motor neuron injury that leads to 
regeneration of neuromuscular synapses and consequently delays ALS progression (Williams et al, 
2009). 
 A recent study provided evidence that miRNA function is crucial in spinal motor neuron 
(SMN) diseases and highlighted the potential role of miR-9 in neurodegeneration (Haramati et al, 
2010). It was observed that mice with miRNA dysfunction in spinal motor neurons (MNDicer 
mut 
mice) showed features of spinal muscular atrophy (SMA) including sclerosis of the spinal cord ventral 
horns, myofiber atrophy and denervation. Moreover, the authors verified that the heavy neurofilament 
subunit is a target of miR-9, a miRNA that is specifically down-regulated in SMA. It has been 
reported that miR-9 with miR-124 plays a role in neuronal differentiation (Yu et al, 2008; Yoo et al, 
2009). 
 In summary, these studies provide evidence for a major role of miRNAs in MND, instigating 
further investigation of miRNA-based mechanisms in ALS pathogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 16 
1.6. Background 
 In preliminary work, laser capture microdissection was performed to establish miRNA 
profiles in 40-day-old mice carrying the G93A SOD1 mouse mutation since the expression of 
miRNAs are highly expected to be changed as a secondary consequence of neurodegeneration and 
death in ALS. Using miRNA specific chips (TaqMan® Array MicroRNA Cards, Applied Biosystems) 
2 miRNAs were identified, which were dramatically upregulated before disease onset. However, since 
RNA used in this preliminary work was very degraded, these results were not considered reliable.  
1.7. Aims of this thesis 
The aims of this thesis were to: 
I. Optimize Laser capture microdissection of spinal motor neurons in presymptomatic (P40)  
SOD1
G93A
 mice. 
II. Produce high quality RNA from laser captured cells. 
III. Validate candidate microRNAs chosen from preliminary microarray analysis of RNA from 
SOD1
G93A
 mice compared to wild-type.  
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2. Materials and Methods 
2.1. Animals 
2.1.1. SOD1G93A transgenic mice 
  The colony of mutant mice expressing the human SOD1 
G93A
 transgene was derived from 
B6.Cg-Tg (SOD1*
G93A
) 1Gur/J mice purchased from Jackson Laboratories and was maintained by 
breeding male transgenic animals to female inbred mice C57BL/6J. Only male hemizygous transgenic 
mice were used for breeding since females carrying the SOD1 
G93A 
mutation were shown to have 
reduced fertility (Ho Y.S. et al, 1998).  
 All the experiments were performed using female transgenic SOD1 
G93A
 mice as gender has 
been shown to influence survival of SOD1 mutant mice (Heiman-Patterson TD et al, 2005). Six mice 
at 40 days old (presymptomatic stage of ALS) were studied including SOD1 
G93A
 transgenic mice 
(n=3) carrying the mutant form of human SOD1 (glycine to alanine substitution at position 93) and 
litter matched wild-type (WT) mice (n=3) that were used as controls to minimize genetic variation. 
  40-days-old SOD1G93A transgenic and nontransgenic control littermates were sacrificed by 
CO2 asphyxiation in compliance with Schedule I of the UK Animals (Scientific Procedures) Act 1986. 
All procedures used on mice were carried out in the Oxford University Animal Facility. 
 
2.1.2. Genotyping 
 The genotyping of SOD1
G93A
 transgenic and WT mice was determined by analysis of DNA 
extracted from ear clips of mice younger than 40 days and from tail tips from 40-days-old mice. For 
DNA extraction, ear clips and tail tips (0.5cm) were digested in 100 and 200 μl DirectPCR Lysis 
Reagent (Viagen Biotech®) with 3 and 5 μl Proteinase K (15 mg/ml, Roche®), respectively. Lysis of 
tissue biopsies was performed overnight at 55°C. The lysates were then heated at 85°C for 45 min and 
centrifuged 10 min at 10,000 x g. The resulting supernatants were used in 25 μl PCR reactions.  
 A single multiplex PCR reaction was prepared using the components shown on table 2.1, 
including 5 ng/μl of template DNA, Taq DNA polymerase (Sigma®) and combined specific primer 
pairs forward (F) and reverse (R) for the transgene hSOD1 (SOD1 F and SOD1 R) and for the 
reference gene mIL2 (SOD1 Ctrl F and SOD1 Ctrl R). 
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Table 2.1 Multiplex PCR Master mix reaction components for a final reaction volume of 25 μl used 
for genotyping SOD1 
G93A
 mice and WT littermates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The primers for the transgene hSOD1 were IMR113 (forward) and IMR114 (reverse), 
which amplify a 236 base pair product. The primers for the gene mIL2 (internal positive control) 
were IMR042 (forward) and IMR043 (reverse), which amplify a 324 base pair product. The 
concentration of these primers was 10 µM and their sequences are indicated on table 2.2. 
 
PCR Master mix reaction 
components 
Volume for one 
sample (μl)  
Nuclease-free water 16.8 
10x dNTP mix  0.5 
Taq DNA polymerase (SIGMA) 0.2 
10x buffer 2.5 
SOD1 F (10µM) 1 
SOD1 R (10µM) 1 
SOD1 Ctrl F (10µM) 1 
SOD1 Ctrl R (10µM) 1 
Template DNA (5 ng/µl) 1 
Total 25 
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Table 2.2 PCR primer pairs of transgene and internal positive control used for genotyping SOD1 
G93A
 
mice and WT littermates. 
Primer Sequence 5’-3’ Product size (bp) 
SOD1 F (IMR0113) CAT CAG CCC TAA TCC ATC TGA 
236  
SOD1 R (IMR0114) CGC GAC TAA CAA TCA AAG TGA 
SOD1 Ctrl F (IMR7338) CTA GGC CAC AGA ATT GAA AGA TCT 
324  
SOD1 Ctrl R (IMR7379) GTA GGT GGA AAT TCT AGC ATC ATC C 
 
 The PCR reaction was performed for 35 cycles in a DNA thermal cycler according to the 
cycling conditions specified on table 2.3. 
Table 2.3 Cycling conditions used for genotyping SOD1 
G93A
 mice and WT littermates. 
Step Temperature ( °C) Time 
Initial denaturation 95  3 min 
Denaturation 95  30 s 
Annealing 60  30 s  (x35 cycles) 
Elongation 72  45 s 
Final Elongation 72  2 min 
Hold 4  ∞ 
 
 The 25 µl of each PCR product with 5 µl Orange G loading buffer was loaded on 1.5% 
1xTBE/ethidium bromide agarose gel prepared by dissolving 2.25g agarose in 150ml 1x TBE buffer 
diluted from 5x TBE containing in 1L, 0.5g NaOH (Mw 40g), 54g Tris Base (Mw 121.10g), 27.5g 
Boric Acid (Mw 61,83g) and 3.7g EDTA (Mw 372.24g). 
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 Electrophoresis of PCR products was performed in 1X TBE at 110V for 45 min and then 
visualized under Ultra-violet (UV) light illumination. 
 
2.1.3. Lumbar spinal cord dissection 
 After death, mice were quickly dissected to remove the whole vertebral column. RNase Zap 
(Ambion®) was used to clean all the instruments and working surfaces before use. 
The spinal cord (SC) was extracted using a 20 ml syringe filled with GIBCO Phosphate Saline 
(PBS) pH 7.2 (Invitrogen®) with a 18-guage needle inserted into the vertebral column (Meikle A. D. 
and Martin A. H., 1981).  
The SC was ejected at the cervical end of column vertebral by hydraulic pressure (figure 2.1) and 
then was cut in order to discard the cervical, thoracic and sacral tracts. The lumbar region of spinal 
cord was isolated since the ALS-like mice have clinical manifestation of hindlimb paralysis and spinal 
cord motor neuron degeneration (Gurney M.E. et al, 1994). 
The isolated lumbar tract was embedding in optimal cutting temperature compound (OCT) 
compound, immediately frozen on dry ice and stored at -80°C until use. All procedures were 
conducted under strict RNase free conditions to avoid RNase contamination in all further experiments. 
 
 
Figure 2.1 Spinal cord removal method from vertebral column of presymptomatic transgenic 
SOD1
G93A
 and WT mice. 
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2.2. Histology 
2.2.1. Cryostat sectioning 
 The samples of OCT frozen SC were sectioned in the transversal plane (- 20ºC) at a thickness 
of 10 μm on a cryostat (Bright®) (previously cleaned with 100% ethanol).  A maximum of 6 sections 
per slide were mounted onto 1.0 PEN (polyethylene naphthalate) membrane slides (Carl Zeiss®) 
required to perform Laser Capture Microdissection (LCM). These slides were previously treated with 
RNase Zap (Ambion®), washed in RNAse-free-water and air-dried in a decontaminated area. 
 Every effort was made in order to avoid RNA degradation by RNAses when handling tissue 
blocks, slides, and tissue sections.   
 
2.2.2. Fixation and Hydration 
 The sections were immediately fix and hydrate, after they were cut, by dipping up and down 
the slides in graded ethanol/water dilution series of 95%, 75% and 50% (for 30 s in each solution) at -
20ºC. The ethanol solutions used were previously treated with ProtectRNA™ RNase Inhibitor 
(Sigma®). 
 
2.2.3. Cresyl violet staining 
 The sections were stained with 1% cresyl violet for 45 seconds. The stain was prepared by 
dissolving cresyl violet acetate powder (Sigma®, C1791) in 50% ethanol/RNase free water. The 
prepared cresyl violet was then heated at 55ºC for ~2 hour and kept rotating overnight at room 
temperature in order to complete dissolve and filtered before use. 
 
2.2.4. Washing and Dehydration  
  Following staining, the sections were washed to remove excess stain and dehydrated in 
graded ethanol/RNase free water dilution series of 50%, 75%, 95% (previously treated with RNase 
Inhibitor) and 3x100% for 30 s each at room temperature. The 100% ethanol solutions were prepared 
using Molecular sieves 4 Å-beeds 8-12 mesh (Sigma®) to absorb water.  
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 The slides were further treated with xylene for 30 s and 5 min and allowed to air dry for 3–5 
min at room temperature. The prepared slides with fresh sections were transported straight away in a 
box containing drying perls Orange (heavy metal free) (Sigma®) to the LCM room. 
 
2.3. Laser Capture Microdissection (LCM) 
 Laser Capture Microdissection (LCM) is a technique for isolating highly pure cell populations 
of specific morphologically identical cells from a heterogeneous tissue section. The LCM system was 
developed during the mid 1990s by Dr Emmert-Buck and his colleagues at the National Institutes of 
Health, USA (Emmert-Buck et al, 1996). 
 Biological tissues are complex heterogeneous structures composed of many cell types, which 
are morphologically and functionally distinct. The analysis of whole tissue samples lead to results 
usually determined by the major or predominant cell type, which may difficult to uncover relevant 
changes occurring in a particular type of cells. Therefore, it is crucial to analyze specific cell types in 
order to obtain significant data to identify and characterize biological processes. LCM has been very 
relevant for obtaining specific groups of cells, when the cell type of interest forms only a small 
proportion of the cells present in a tissue, allowing pure, homogeneous sample preparation and 
increasing the accuracy of molecular analysis. 
 LCM system includes a microscope connected to a computer for laser control and where 
tissue sections are visualized and cells of interest are selected to be collected. This system utilizes a 
narrow beam UV laser (less than 1 µm in diameter) to cut around the selected cells with a high degree 
of accuracy and precision.  A pulse from microdissection laser and pressure catapulting system is then 
used to catapult the dissected cells into a collection tube cap (Kuhn et al., 2006; Murray GI., 2007). 
 Since motor neurons represent only 10% of spinal cord cells (Schaffner et al., 1983), in the 
present study, LCM was performed to obtain pure populations of motor neurons. 
 LCM was carried out immediately after preparation of SC sections in order to isolate motor 
neurons that were identified by location in ventral horn using 5x amplification and by size (at least 
25µm in diameter) (Perrin FE et al, 2005) using 40x amplification.  
 The motor neurons were selected, cut with a UV-laser using PALM MicroBeam system (Carl 
Zeiss®) and Robot software  (version 2.2) and then collected into a tube cap with 40µl of lysis 
solution (RNAqueous-Micro Kit, Ambion®). Approximately 200 motor neurons were captured in one 
session during an hour and then were briefly centrifuged and frozen on dry ice and stored at -80 °C.  
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The whole process of SC sections preparation followed straight away by LCM was repeated until a 
total of 600 motor neurons were collected per sample. 
 
2.4. miRNA/RNA extraction 
 Total RNA (including miRNA) was extracted using RNAqueous-Micro Kit (Ambion®) 
following manufacturer's protocol from 600 cells (200 pooled together) in 100 μl volume of lysis 
solution for each sample of a total of 6 samples (3 SOD1 
G93A
 and 3 WT).  
 The lysate was mixed with 1.25 volumes of ethanol to recover large and small RNAs 
including tRNAs, 5S rRNA and microRNAs. The extracted RNA was then treated with DNase to 
remove trace amounts of genomic DNA.   
 
2.5. RNA quantification and quality control 
 RNA concentration was determined using a Quant-iT RiboGreen RNA reagent kit 
(Invitrogen®) according to the manufacturer's instructions. Quant-iT
TM
 RiboGreen RNA reagent is an 
ultrasensitive fluorescent nucleic acid stain that allows the quantitation of as little as 1 ng/mL RNA 
with a fluorescence microplate reader and fluorometer using fluorescein excitation and emission 
wavelengths (Jones L.J. et al, 1998). The use of this reagent avoid the major disadvantages of the most 
commonly used absorbance-based method for nucleic acid quantitation (determination of absorbance 
at 260 nm), such as large relative contribution of proteins and free nucleotides to the signal, the 
interference caused by contaminants and the relative insensitivity of the assay (an A260 of 0.1 
corresponds to a 4 μg/mL RNA solution). Fluorescence of each sample was measured using the same 
instrument parameters to those used when generating the standard curve. To minimize photobleaching 
effects, the time for fluorescence measurement was kept constant for all samples. The fluorescence 
value of the reagent blank was subtracted from that of each sample. Corrected data was used to 
generate a standard curve of fluorescence versus DNA concentration. RNA concentration of each 
sample was determined from the standard curve generated.  
 Analysis of total RNA structural integrity was conducted by lab-on-chip capillary gel-
electrophoresis using the Agilent Bioanalyzer 2100 with the RNA 6000 Pico chip (Agilent 
Technologies). RNA samples were electrophoretically separated on a micro-fabricated chip and 
subsequently detected via laser induced fluorescence detection. The 28S/18S ratios and RNA Integrity 
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Number (RIN) were automatically generated by Bioanalyzer 2100 software.  RIN number is 
determined from the shape of the curve in the electropherogram, in order to get a robust and reliable 
prediction of RNA quality not only based on 28S/18S ratios but also taking other critical 
characteristics of several regions of the recorded electropherogram into account. The RIN software 
algorithm allows the classification of total RNA on a numbering system from 1 to 10, with 1 being the 
most degraded profile and 10 being the most intact (Schroeder A. et al, 2006) (Fig.2.2). 
 
 
 
 
 
Figure 2.2 RNA quality of extracted total RNA measured using Agilent 2100 bioanalyzer. The 
distinction with regard to integrity was based 28S/18S ratios and RIN of each sample. Example 
electropherograms from intact RNA sample showing high 18S and 28S rRNA and degraded RNA 
samples showing elevated threshold baseline and a shift in the RNA size distribution toward smaller 
fragments (Figure adapted from Schroeder A. et al, 2006). 
 
2.6. Reverse transcription and quantitative PCR (RT-qPCR) 
 For miRNA cDNA synthesis, miRNA reverse transcription (RT) was conducted using the 
TaqMan MicroRNA reverse transcription kit (Applied Biosystems®), according to manufacturer’s 
protocol.  
 In order to validate previous microarray data (table S1) and detect the expression of mature 
miRNAs found changed, including miR-34c and miR-182, firstly stem specific stem-loop RT primers 
(TaqMan Micro RNA Assays, Applied Biosystems®) were used to perform reverse transcription (RT), 
followed by qPCR. Another approach detect the miRNAs expression was further implemented by 
using Megaplex 
TM
 Pool RT primers (Applied Biosystems®), followed by an amplification step of 
cDNA prior to qPCR.  
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2.6.1. RT-qPCR TaqMan MicroRNA Assays 
 The TaqMan® real-time RT–PCR for miRNA quantification was performed in two steps: RT 
and real- time PCR schematically represented in Fig. 2.3 (Chen C. et al, 2005).  
 In the RT step, cDNA was reverse transcribed from total RNA samples using commercially 
available specific stem-loop miRNA primers from the TaqMan® MicroRNA Assays and reagents 
from the TaqMan® MicroRNA Reverse Transcription Kit. The stem–loop RT primers bind to the 3’ 
end of miRNA molecule that is reverse transcribed to cDNA with a reverse transcriptase. 
 The TaqMan® MicroRNA assays and MultiScribe
TM
 Reverse Transcriptase were used to 
prepare each 15 μl RT reaction master mix consisting of 7 μl master mix, 3 μl of each primer and 5 μl 
total RNA (table 2.4).  
 
Table 2.4 RT reaction master mix components in a final volume of 15 μl  including 7 μl master mix, 3 
μl of each primer and 5 μl total RNA. 
 
 
 
 
 
 
 
 
 The parameter values used to program the thermal cycler to perform RT reaction are specified 
on table 2.5.  
 
 
RT Master mix components 
Volume for one sample 
(μl)/ 15 μl reaction 
100mM dNTPs (with dTTP) 0.15 
MultiScribe
TM
 Reverse Transcriptase, 50 U/μL 1.00 
10 Reverse Transcription Buffer 1.50 
RNase Inhibitor, 20U/μL 0.19 
Nuclease-free water 4.16 
Total 7.00 
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Table 2.5 Cycling conditions to perform RT reaction followed by qPCR. 
Temperature (ºC) Time (min) Stage 
16  30  Hold 
42  30  Hold 
85  5  Hold 
4  ∞ Hold 
 
 In the real time PCR step, the RT product is amplified using TaqMan® Universal PCR Master 
Mix together with TaqMan® PCR assay that includes miRNA-specific forward primer, reverse primer 
and TaqMan® probes. The TaqMan® probes contain at the 5′ end a reporter dye (FAMTM dye) and at 
3’ end a minor groove binder (MGB) and a nonfluorescent quencher (NFQ). The TaqMan® probe 
anneals specifically to the complementary target sequence between the forward and reverse primer 
sites. The cleavage of probes hybridized to the target by the DNA polymerase separates the reporter dye 
from the quencher dye resulting in increased fluorescence by the reporter.  
 
 
 
 
 
 
 
Figure 2.3 Schematic description of RT–PCR TaqMan® MicroRNA Assay chemistry including two 
steps. The miRNA stem-loop RT primer binds to the specific miRNA target and is extended during the 
RT reaction (step 1) and real-time PCR (step 2).  F: FAM dye, Q: quencher dye (Chen C. et al, 2005). 
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 To evaluate the primers efficiency, qPCR was performed using serial dilutions of cDNA. The 
log-transformed cDNA input was plotted against Ct values (cycle threshold, which is a cycle number 
based on the point where the fluorescence response rises above the background level and is measured 
in the exponential phase) and the slope of the resulting curve was then used to calculate the efficiency 
(E) according to equation E = (10
-1/slope
 – 1) x 100.  
 The real time PCR reactions were performed in triplicate using Taqman® 2X Universal PCR 
Master Mix (Applied Biosystems®) in a final volume of 20μL (table 2.6), according to the 
manufacturer’s protocol.  
 
Table 2.6 Real-time PCR reaction mixture components. 
 
 
 
 
 
 
 
 
 
 The cycling conditions used to perform real-time PCR on a StepOnePlus Real-time PCR 
machine (Applied Biosystems®) are shown on table 2.7. 
 
  
Component Volume (μL) / 20-μL 
Reaction 
TaqMan® MicroRNA Assay (20) 1.00 
Product from RT reaction  1.33 
TaqMan® 2 Universal PCR Master Mix, 
No AmpErase UNGa 
10.00 
Nuclease-free water 7.67 
Total Volume 20 
 28 
Table 2.7 Parameter values used to program the thermal cycler to perform real-time PCR. 
 
 
 
 
 
  
 The relative expression of miRNAs was determined using the comparative Ct method. The Ct 
values of both the calibrator and the samples of interest were normalized to endogenous control (ΔCt = 
Ct Target - Ct Endogenous Control). The ΔCt values were normalized relatively to a control or calibrator  (ΔΔCt 
= ΔCt Sample - ΔCt Calibrator). The 2
-ΔΔ Ct
 value was then determined for each sample. The endogenous 
controls used in all the experiments for quantifying mature miRNA expression were sno-RNA234 and 
snoRNA-202 that showed the least variation across all tissue samples and cell lysates. Three biological 
and triplicates were utilized in all experiments.   
 
2.6.2. RT-qPCR Megaplex TM Pool with cDNA preamplification step 
 Relative quantitation using Megaplex 
TM
 Pools was performed in three steps: RT-PCR, 
preamplification and real-time PCR. 
 In the RT step, cDNA was reverse transcribed from total RNA samples, using RT Megaplex 
TM
 primers and reagents from TaqMan MicroRNA Reverse Transcription Kit. Megaplex 
TM
 RT Rodent 
primer pools A and B (TaqMan) allow reverse transcription of 375 miRNAs each (figure S1) and 6 
controls including Mamm U6 were used to perform RT reaction followed by a preamplification step of 
cDNA. Megaplex 
TM
 RT were performed with 3 μL of total RNA (1 ng/µL) and 4.5 μL of Megaplex 
TM
 RT reaction (components shown on table 2.8).  
 
 
 
Step Temperature (°C) Time Step 
Enzyme activation 95  10 min Hold 
Denaturation 95  15 sec 
40 cycles 
Annealing/elongation 60  60 sec 
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Table 2.8 RT reaction Mix components in final reaction volume of 7.5 μl. 
 
 
 
 
 
 
 
 
 
 
  
 Megaplex 
TM
 RT reaction was performed using the cycling conditions indicated on table 2.9 
and was followed by a preamplification step prior to qPCR. 
 
Table 2.9 Cycling conditions used for Megaplex 
TM
 RT reaction. 
Temperature  Time Stage 
16 °C 2 min  
Cycle (40 cycles) 42 °C 1min 
50 °C 1 sec 
85 °C 5 min Hold 
4 °C ∞ Hold 
RT reaction Mix components Volume for one sample 
(μl)/ 15 μl reaction 
Megaplex 
TM
 RT Primers (10x) 0.80 
dNTPs with dTTP (100 mM) 0.20 
MultiScribe Reverse Transcriptase (50 U/μL) 1.50 
10x RT Buffer 0.80 
MgCl2 (25 mM) 0.90 
RNase Inhibitor (20 U/μL) 0.10 
Nuclease-free water 0.20 
Total 4.50 
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 In the preamplification step, PCR products were uniformly amplified from cDNA templates 
using the Megaplex 
TM
 PreAmp Primers and the TaqMan PreAmp Master Mix in a 22.5 μl reaction 
(components are described on table 2.10) and the cycling conditions presented on table 2.11.) 
 
Table 2.10 PreAmp Reaction Mix Components. 
 
 
 
 
 
 
 
Table 2.11 PreAmp Reaction Mix Cycling conditions. 
 
 
 
 
 
 
 
 
 
 
PreAmp Reaction Mix Components Volume for one 
sample (μl) 
TaqMan® PreAmp Master Mix, 2x  12.5 
Megaplex 
TM
 PreAmp Primers (10X) 2.5 
Nuclease-free water 7.5 
Total 22.5 
Stage Temp (°C) Time 
Hold 95  10 min 
Hold 55  2 min 
Hold 72  2 min 
Cycle (12 Cycles) 
95  15 sec 
60  4 min 
Hold 
(a)
 99.9  10 min 
Hold 4  ∞ 
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(a) This step was required for enzyme inactivation 
 Real-time PCR step and miRNAs relative expression was accomplished as previous described 
on 2.6.1. Endogenous control used in all the experiments was U6Mamm, which was found to show 
stable expression across all the samples studied. Three biological and triplicates were utilized in all 
experiments. 
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3. Results 
3.1. Genotyping of WT and SOD1G93A Mice Littermates 
 The mice littermates in each new generation were successfully genotyped by identification of 
the PCR products size.   
 Figure 3.1 shows one of the genotyping experiments performed. SOD1G93A transgenic mice 
were efficiently distinguished from WT by originating PCR products of the expected characteristic 
size. The use of a 100pb DNA ladder as a mass and size standard during electrophoresis allowed the 
estimation of the fragment band sizes.  The presence of the transgene (SOD1) was identified by 236bp 
band and the reference gene (mIL2) was identified by 324bp band. From 5 samples of mice 
littermates, 3 were identified as SOD1G93A transgenic mice and 2 as WT. The absence of bands for 
negative control shows there was no contamination.  
 Once distinguished which ones were WT and SOD1G93A transgenic mice, 3 of each were 
subsequently used for the experiments.  
 
Figure 3.1 Ethidium bromide–stained 1.5% agarose gel for genotyping of 5 samples from mice 
littermates. Lane 1: 100 bp marker ladder; lanes 2 and 3: SOD1
G93A
 positive controls (236bp).; 
lanes 4 and 5: WT positive controls (324bp).; lane 6: negative control; lane 7-11: 5 samples (3 WT 
and 2 SOD1
G93A
). Black arrows indicate fragment sizes of human SOD1 (236bp) and internal 
control mIl2 (324bp). 
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3.2. Motor Neurons Isolation by LCM 
 
 To study the differential miRNA expression that may occur during early events of ALS and 
eventually predispose or trigger motor neuron degeneration, it was necessary to use LCM in order to 
isolate motor neurons from lumbar spinal cord.  
 Spinal cord samples were successfully sectioned and stained with clear histological results as 
shown on Fig.3.2, allowing motor neurons identification. 
 As expected in a presymptomatic stage of ALS, there were no evident differences in number 
and morphology of motor neurons between 40-day-old WT and SOD1
G93A
 mice. Approximately 40-
60 motor neurons were found in the ventral horn of spinal cord (Fig.3.2 B and F) with a diameter 
between 25 and 50 µm (C and G). Morphology of motor neurons appeared similar in both WT and 
mutant mice, showing classical neuronal features including a large cell body (soma) with a single 
nucleus and no signs of neurodegeneration (Fig.  3.2 C and G).  
  Starting with low amount of LCM cells may strongly compromise the results of downstream 
applications. The Applied Biosystems TaqMan microRNA Array and qPCR require a minimum 
quantify of 1ng starting total RNA. It was reported in the literature that a total of 500 cells is 
expected to yield around 5 ng of total RNA (Perrin et al, 2005; Ferraiuolo et al, 2007). Therefore, 
LCM was performed typically yielding a minimum of 600 motor neuron cells per sample. After 
LCM, the remaining spinal cord tissue was intact (Fig. 3.2. B, D, F and H), confirming the high 
selectivity of the microdissection procedure.  
  
 
 
 
 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Laser Capture Microdissection (LCM) of motor neurons from 1% cresyl violet stained 
lumbar spinal cord (SC) sections of 40-day-old SOD1
G93A
 (A, B, C, D) and WT (E, F, G, H) mice.  
(A, E) SC sections prior to LCM. (B, F) SC sections (A) and (E) after capture of motor neurons 
localized in the ventral horn. (C, G) Selected motor neurons for LCM showing a diameter at least 
of 25 µm. (D, H) SC after capture of motor neurons (higher magnification of (B) and (F)). Pictures 
were taken at 5x magnification (A, E, B, F) and 40x magnification (C, D, G, H). Scale bar 
represents 25 µm in (C, D, G, H) and 200 µm in (A, B, E, F).  Morphology of motor neurons was 
similar in WT and SOD1
G93A
 SC with no signs of degeneration. 
Pre-LCM Post-LCM 
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3.3. RNA Quantity and Quality Assessment 
3.3.1. Quantity of total RNA was accurately determined by RiboGreen Assay 
  Quantification of RNA is essential to check RNA quality prior to the following 
experiments. To ensure that enough RNA yield was obtain after total RNA extraction from 
microdissected motor neurons, RNA quantity was measured via NanoDrop (ND) 1000 
spectrophotometer, Quanti-iT Ribo Green Assay and Agilent 2100 Bioanalyzer.  
  Although Agilent 2100 Bioanalyzer can determine both integrity and quantity of RNA, it has 
been considered a quantification method that exhibits lower precision and accuracy than Quanti-iT 
Ribo Green Assay and ND-1000 spectrophotometer in 0.05 – 500 ng/μl range (Aranda R. et al, 2009). 
Therefore, to ensure that enough RNA yield was obtain after total RNA extraction from 
microdissected motor neurons, RNA quantity was measured in the 0-10 ng/µl range via ND-1000 
spectrophotometer and Quanti-iT Ribo Green Assay. RNA samples from three sections after LCM 
were used to test these two quantification methods in different dilutions in a 0.25-1 ng/μl range. 
 The low-range standard curve used to estimate the RNA concentration using Quanti-iT Ribo 
Green Assay was consider linear since it showed a correlation coefficient (R
2) ≥ 0.995 (Fig. 3.3).  This 
curve was traced using the fluorescence values showed on table 3.1. 
 
Table 3.1 RFU corrected values and RNA concentration of RNA standard sample in a final volume 
assay of 200μl. 
 
 
 
 
 
 
 
RNA standard RFU 
RNA standad RFU 
corrected 
[RNA standard] 
(ng/200μl) 
65000 59526 10 
64443 58969 8 
51381 45907 6 
34279 28805 4 
20799 15325 2 
12701 7227 1 
9838 4364 0.5 
5474 (blank) 0 0 
 37 
 
 
 
 
 
 
 
Figure 3.3 Standard curve for RNA concentration using RiboGreen assay. 
  
 Results using RNA samples in a 0.25-1ng/μl range showed that Quanti-iT Ribo Green Assay 
was more accurate than NanoDrop in measure small amounts of RNA (Table 3.2).  
 
Table 3.2 RFU corrected values and RNA concentration of RNA ([RNAinitial]=5.7 ng/μl diluted to 
1ng/μl) sample in a final volume assay 200μl. 
 
 
 
 
 
 
 
 Moreover, it has been previously reported in literature that Quanti-iT Ribo Green Assay 
exhibits high precision and accuracy in a 1-0.05 ng/μl range, while NanoDrop demonstrates this in a 
RNA  RFU
a
 [RNA ] 
(ng/200µl) 
[RNA ] 
(ng/200µl)  
RiboGreen Assay 
[RNA] 
(ng/200µl) 
NanoDrop 
6636 1 0.91  1.99 
8007 1 1.06 1.63 
5712 0.5 0.75 1.50 
4595 0.5 0.60 1.61 
3884 0.25 0.40 1.34 
3513 0.25 0.35 1.43 
a
 blank corrected values  
y = 7411,3x + 179,09 
R² = 0,999 
0
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higher range (5-500 ng/μl). Consequently, the Quanti-iT Ribo Green Assay was chosen for 
quantification of RNA. 
3.3.2. Quality of total RNA improves substantially with RNase Inhibitor  
 The assessment of RNA integrity is a crucial step since using high RNA quality is essential 
for obtaining meaningful qRT-PCR and micro-array data. Total RNA quality was verified using 
Agilent RNA 6000 Pico chip on a 2100 Bioanalyser. For each sample, RNA profiles were generated 
allowing analysis of RNA integrity by visualization of 28S/18S rRNA peak ratio, 18S and 28S 
ribosomal RNA bands, and RNA integrity number (RIN).  
 Initially, significant RNA degradation was found in total RNA extracted from cells collected 
by LCM, indicated by an elevated threshold baseline, absence of 28S peak and broadening of 18S 
peak. Since 28S rRNA degrades faster than the 18S, only one band for 18S and many lower bands 
corresponding to fragments resulting from degradation were identified in gel analysis and a RED alert 
was displayed meaning strong degradation (Fig.3.4 D).  
 
Figure 3.4 Preservation of RNA integrity from LCM single cells, by addition of RNase Inhibitor and 
staining optimization. (A) Section stained in the absence of RNase Inhibitor. (B) Section stained with 
non-treated stain and fixed and dehydrated in ethanol solutions treated with RNase Inhibitor. (C) 
Section stained in the presence of RNase Inhibitor in the stain and fixed and dehydrated in the ethanol 
solutions previous treated with Rnase Inhibitor. (D-F) RNA was extracted from motor neurons 
collected by LCM from sections A, B and C, respectively. RNA quality was assessed using Agilent 
RNA 6000 Pico chip on a 2100 Bioanalyser. 
E D 
A B     C 
     F     
RIN=N/A RIN=6.8 RIN=7.1 
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 The main cause of RNA degradation during tissue preparation and LCM protocol was likely 
the presence of water in ethanol solutions since RNA has been described as readily endangered by 
ubiquitous RNAses - catalyzed hydrolysis. Furthermore, RNase Inhibitor was shown to improve RNA 
quality in the literature (Kube M.D. et al, 2007; Bevilacqua C. et al, 2010). Therefore, RNase inhibitor 
was included in ethanol/water solutions, except xylene, in which it is insoluble. As consequence, RNA 
quality was successfully increased, as evidenced by clear definition of both 18S and 28S peaks and 
decreased threshold baseline, resulting in a RIN above six, which indicates high RNA quality (Fig.3.4 
B).  
 In order to further improve RNA quality, RNase Inhibitor was added to 1% cresyl violet. 
Although greater RNA quality was achieved using this protocol (RIN above seven), as showed on Fig. 
3.4 F, spinal cord sections showed inferior staining quality, leading to a less effective identification of 
motor neurons. The RNase inhibitor, when added to the stain, was found to precipitate cresyl violet, 
impairing staining (Fig. 3.4 C), resulting in a lower number of collected cells by LCM.  
 As staining optimization is critical for quick and accurate LCM, experiments were carried out 
using untreated stain and RNase Inhibitor treated ethanol/water solutions to ensure both high RNA 
quality and high selectivity of the microdissection procedure.  
 Electropherograms presented in Fig.3.5 show high quality of RNA extracted from 600 motor 
neurons collected by LCM from 3 SOD1
G93A
 mice (Fig.3.5 A-C) and WT litter-matched mice (Fig.3.5 
D-F). Different features covering several aspects of the measurement are indicated for each RNA 
sample in Fig.3.5 confirming that RNA remained intact and could be used for downstream 
applications including microRNA arrays and RT-qPCR. All electropherograms exhibit low threshold 
baselines, clearly defined high 18S and 28S peaks resulting in a ribosomal ratio of approximately 1.0. 
According to literature, a 2.0 28S/18S ratio is reported as perfect (Mueller et al, 2004), although in 
practice this value is difficult to obtain (Fleige, S. and Pfaffl M. W., 2006). Moreover, a 28S/18S ratio 
lower than 2.0 as obtained is not necessarily indicative of decreased RNA integrity (Imbeaud et al, 
2005) as can be proved by a high RIN (above six, approximately seven in some cases) obtained for all 
samples. There were no significant changes between RNA quality from SOD1
G93A
 mice and WT litter-
matched mice samples. 
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Figure 3.5 Quality of extracted RNA from 600 motor neurons collected by LCM samples was 
analysed using Agilent RNA 6000 Pico chip, on a 2100 Bioanalyser. RNA samples from 3 
SOD1G93A mice (A-C) and WT litter-matched mice (D-F). All RNA profiles show clear definition of 
the 18S and 28S peaks. 
   A    D 
   B 
   C 
    E 
    F 
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 Furthermore, the integrity of RNA extracted from three spinal cord sections pool together, 
before staining (C1) and after LCM (C3) was assessed in order to control RNA quality during the 
procedure (Fig.3.6). Overall, results from three spinal cord sections revealed a higher RIN (above 
seven indicating very high RNA quality), when compared to the ones obtained from isolated LCM 600 
cells.  It was verified that higher amount of collected cells by LCM increases the RNA yield, allowing 
a more accurate assessment of RNA integrity, usually resulting in greater RIN. Moreover, some 
degree of RNA degradation is expected from single cell LCM, due to unavoidable exposure of the 
sample to degradation factors during cell collection (Craven, R.A. et al, 2002). To ensure high RNA 
quality, cell collection was performed within 1 hour from staining and fixation.  
 There were no significant differences in quality between RNA extracted prior to staining and 
after LCM in both WT and mutant samples. Thus, LCM was successful optimized ensuring RNA 
integrity maintenance during fixing, staining, dehydrating, LCM and RNA extraction procedures. 
 
 
 
 
 
 
 
 
 
Figure 3.6 Quality of extracted RNA from 3 spinal cord sections from WT (A,B) and SOD1
G93A
 (C, 
D) mice was analysed using Agilent RNA 6000 Pico chip on a 2100 Bioanalyser. RNA extracted 
before staining and LCM(C1) (A,C)  and after LCM (C3) (B,D). All RNA profiles show clear 
definition of 18S and 28S peaks and RIN≥ 7, an indication of high-quality RNA. There were no 
significant changes before and after LCM procedure. 
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 Agilent 6000 Pico chip was able to confirm that high quality total RNA was obtained but it 
does not allow discriminating between different fractions of RNAs. 2100 Bioanalyzer analyzes small 
RNA fraction (<200 nt) but fragments within this fraction with a size of 15–40 nt corresponding to 
miRNAs are not possible to detect in the electropherograms. Moreover, it was shown in literature that 
miRNA quantification using the lab-on-chip technology is influenced by overall total RNA integrity 
(Becker, C. et al, 2010). So, miRNA should not be considered as a solitaire fraction, but always as a 
part of the entire total RNA since RNA degradation is accompanied by the formation of small RNA 
fragments that can lead to an overestimation of the miRNA amount. Therefore, miRNA high quality 
was ensured since high total RNA integrity was confirmed. 
 
3.4. Expression profiling of microRNA using real-time quantitative PCR 
 RT-qPCR was performed using total RNA from whole spinal cord (reference sample) in order 
to construct a standard curve using a tenfold dilution series of 40 ng/µl total RNA as starting amount. 
Threshold Cycle (CT) values were plotted in function of input RNA quantity (Fig.3.7). These plots of 
RNA concentration versus CT exhibit perfect linearity, indicating a correlation coefficient of the line  
(R
2
) approximately 1 (R2> 0.99) and slopes between -3.10 and -3.58.  
 The slope of each standard curve was used to determine reaction efficiency. The primers used 
to detect miR-182, miR-34c, miR-234 and miR-202 showed high efficiencies between 90% and 110%. 
The sensitivity was found acceptable in the quantitation of total RNA concentrations (0.4 - 40 ng/µl) 
since miRNA targets were detected above the background noise of the system in a range of CT values 
between 35 and 25. Reproducibility was satisfactory as the standard deviation between the triplicates 
showed less than 0.5 CT of difference. 
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Figure 3.7 Standard curve analysis depicting perfect linearity and correlation between input quantity 
(40-0.4 ng/µl) and measured Threshold Cycle (CT) value for four different miRNAs (miR-182, miR-
34c, miR-234 and miR-202).  
 Since miRNA specific primers revealed an acceptable efficiency in a range of 40-0.4 ng/ul 
total RNA, subsequently, an amount of 1ng/ul total RNA extracted from 600 motor neurons collected 
by LCM was used to perform RT-qPCR.  
 Initially, in order to validate microarray data and analyse expression of miRNAs that were 
found dramatically changed in LCM motor neurons from SOD1
G93A
 mice relatively to WT mice, RT-
qPCR was performed using TaqMan® microRNA assays. Overall, miRNA specific primers detected 
target miRNAs, producing CT values around 35 for motor neurons collected by LCM samples that 
were about five cycles higher than CT values for three SC sections (C1) samples. Moreover, standard 
deviation (SD) showed an increase of the error with higher CT values, with SD values over 0.8. The 
amplification curves for miR-182 and miR-34c presented very high CT values, indicating that 
amplification of these target sequences occurred later than expected. This result is usually due to low 
RNA quality, not enough template sequence or not optimal reverse transcription (RT). 
 High quality of total RNA extracted from all samples (600 motor neurons collected by LCM 
and three SC sections from both SOD1
G93A
 and WT mice) was confirmed using Agilent 2100 
Bioanalyser prior to RT-qPCR analysis. However, better RNA quality was observed for three SC 
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sections samples compared to the RNA quality of cells obtained by LCM. Therefore, in spite of a great 
progress of RNA quality from cells obtained by LCM was achieved, an even greater improvement of 
RNA quality and yield could result in a more successful RT-qPCR performance. Moreover, low 
amount of template may be a plausible reason for this result, since miRNA-34c and miR-182 may be 
expressed at a very low level in motor neurons compared to remaining cells of spinal cord tissue as 
lower CT values were obtained for spinal cord sections samples compared to CT values of LCM 
collected cells. Furthermore, the control miRNAs used showed lower CT values than target miRNAs 
since they are expressed at high level. 
 Therefore, low amount of template is more likely than low RNA quality as a possible cause to 
explain the obtained results. Then, collect more than 600 cells by LCM would be needed in order to 
ensure reproducible results. However, LCM can be very time-consuming and expensive. 
Consequently, a preamplification step of cDNA was introduced in order to increase the template 
amount using a Megaplex pool of primers to perform RT reaction and Megaplex pool of primers to 
perform preamplification step of cDNA using TaqMan® PreAmp Master Mix kit were used. Overall, 
results with preamplification of cDNA revealed an early amplification, lower CT values, and therefore 
more reliable RT-qPCR results that could further be use for miRNA quantification.  
 Although a decrease of CT values was observed for three SC sections samples, further 
optimization of RT-qPCR performance is required since CT values of LCM motor neurons samples 
remained high (over 30). This indicates that probably more than 600 cells collected by LCM are 
needed for accurate miRNA quantification. Furthermore, introducing a pre-amplification step can be 
concerning, as there is a possibility that the relative miRNA expression levels in the original cell 
population are not maintained.  
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4. Discussion 
4.1. Laser Capture Microdissection: Advantages/ disadvantages and effect 
on quality and yield of RNA 
 
 The main advantage of Laser Capture Microdissection (LCM) is to allow isolating separately 
specific populations of cells from complex heterogenous tissues. This technique enables to identify 
specific cell properties that by the use of homogenized whole tissue samples might be undetected. The 
combination of LCM with quantitative PCR or microarray is a powerful method to acquire relevant 
data of gene expression profiles in distinct cell populations from heterogeneous tissue.  
 Other techniques have been extensively used in attempts to analyze pure cell populations, 
such as cell culture studies and flow cytometry. However, cultured cells might not accurately reflect 
the biological characteristics of the cells from which they are derived because they are subject to 
different environmental factors and resulting data from flow cytometric analysis is not suitable to 
measure and analyze individual cell properties. Therefore, LCM is the technique that permits to obtain 
more accurate and meaningful results from specific cell types. 
 LCM is a major advance in study cell biology but a number disadvantages have been identified 
in diverse studies (Wang W.Z. et al, 2009; Wang S. et al, 2010). This technique  is very expensive as 
special membrane-covered slides have to be used and the microscope and accompanying computer 
hardware and software required are also very costly. Moreover, this technique is highly operator 
dependent and the identification of cell types for microdissection is based on morphologic 
characteristics, requiring experience with histopathological analysis (Liu A., 2010).  
 The main limitation of LCM is the difficult in obtaining consistently high quality and quantity 
of total RNA allowing further analysis using amplification-based techniques.  LCM tend to be 
extremely lengthy and time-consuming technique since numerous cells are required to be collected for 
downstream applications. So, maintaining RNA integrity from small amounts of starting material 
during LCM procedure is one of the major challenges of this technique. LCM is performed at room 
temperature and requires staining of the tissue prior to microdissection, which can affect RNA 
integrity by exposing RNA to chemical components and RNases that are active in aqueous solutions. 
Moreover, freezing samples when strorage may contribute to RNA degradation (Cummings T.J. et al, 
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2001). 
 In this study, optimization of stain using RNase Inhibitor was achieved ensuring both optimal 
histological results and high RNA quality. However, the RNase Inhibitor used to treat ethanol 
solutions during fixation and dehydration steps was a red solution, which impaired the staining, 
therefore an RNase Inhibitor soluble in water, yielding a colorless solution, would greatly improve the 
balance good RNA quality/staining of tissue sections.  
 Moreover, initially RNase Inhibitor was added to the stain and great RNA quality and 
histological results were achieved. However, a decrease of staining quality was observed in sucessive 
experiments due to cresyl violet precipitation after adding RNase Inhibitor despite it had been properly 
stored. Previous studies had reported that RNAse Inhibitors were found to be incompatible with cresyl 
violet (Fleige S. and Pfaffl M.W., 2006). Moreover, is highly likely that in this study, over time, 
atmospheric CO2 had dissolved into RNase-free water used to dissolve cresyl violet, leading to a 
decreased of pH. Recently, it was reported that alcoholic cresyl violet solutions may impair the 
staining, particularly at reduced pH and that adjusting the pH of staining solution with Tris–HCl to 8.0 
prior to use of can contribute to achieve reproducible staining intensities and great tissue visualization 
ensuring high RNA quality (Cummings M et al, 2011). 
 In order to augment the amount of starting material, increasing the tissue thickness was tried as 
an alternative to collect more cells and without spending more time and expensive special slides to 
perform LCM.   
 This technique has been performed in most of studies using very thin sections (5-12 µm) 
(Fernández-Medarde A. et al, 2007). A recent study has reported that 20µm sections equally clear 
visibility of 10 µm sections of brain stained with cresyl violet (Wang W.Z. et al, 2009). However, in 
this study, spinal cord sections stained with cresyl violet with thicknesses higher than 10 µm showed 
impaired visibility and required higher UV cutting energy leading to a less precise LCM procedure.  
 To ensure that RNA integrity is maintained, ideally, tissue cryosections should be obtained 
using a cryostat in vicinity of the room where LCM is performed (Vincent V.A.M. et al, 2002), which 
was one of the difficulties in the present study.  
 The environmental variables such as temperature and humidity can also affect RNA integrity. It 
has been reported that with relative humidity maintained at or below 23%, the LCM process operates 
at high efficiency of capture and did not reduce the quality of RNA for a collection period up to 2 hr 
(Ordway G.A. et al, 2009). Some studies reveal that LCM should be carry out during a maximum time 
of 30 min, to ensure maintenance of RNA integrity and efficiency of capture (Kinnecom 2005; Espina 
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et al., 2006). In present study, the tissue sections were kept as dry as possible using desiccant beeds 
during transport to the room where LCM was performed no longer than 1 hour to avoid RNA 
degradation and collect enough number of cells to optimize both RNA quality and yield. 
 
4.2. Effect of RNase Inhibitor on RNA integrity assessed by Bioanalyser 
  
 Postmortem processes and inadequate sample handling and storage lead to RNA degradation 
due to reactivation of RNAases in tissue sections or as a result of nonenzymatic hydrolysis of RNA 
(Kierzek, 1992; Perez-Novo et al., 2005). Several factors can affect RNA integrity such as increased 
temperature, UV light, chemical components of histological staining and enzymatic degradation.  
 In present study, in the absence of RNase Inhibitor, total RNA assessed by 2100 Agilent 
Bioanalyser was very degraded, despite all steps during tissue handling and LCM procedure was 
carefully controlled to preserve the quality of the RNA. After, introducing RNase Inhibitor, there was 
considerable improvement in quality of RNA recovered from the tissue sections and cells collected by 
LCM. Although in a recent study, there was no considerable improvement on RNA quality using 
RNase inhibitor (Wang S. et al, 2010), in agreement with the observation in this study, a previous 
study reported that RNase inhibitors could significantly improve RNA quality (Kube D.M. et al, 
2007). 
 Starting with low quality RNA may strongly compromise the accuracy of downstream 
applications. Therefore, the assessment of RNA integrity is a crucial step to ensure success of RNA-
based analyses. In this study, the evaluation of RNA integrity was performed using Agilent 2100 
Bioanalyser, which is a microfluidics-based platform for that gives results within 30-40 minutes. The 
advantages of this instrument include automated digital data, improved precision and reproducibility, 
minimal sample consumption and short analysis times.  
 However, it was difficult to obtain consistently high RNA quality assessed by Agilent 2100 
Bioanalyser from cells collected by LCM and tissue sections, using exactly the same staining, LCM 
and RNA extraction protocol. The inconsistent results were found to be due to the bead-immobilized 
DNase I inactivation reagent (Ambion) used for inactivated DNAse I, after Genomic DNA was 
digested by treatment with DNA-free™ DNAse treatment (Ambion) that affected the instrument 
performance. This was verified by comparison of samples after and before DNAse treatment. This was 
also observed in other investigators samples, which were treated with the same DNase procedure in 
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the laboratory.  
 Usually, the presence of genomic DNA can generate false positive signals during RT-qPCR, 
therefore DNase treatment should be performed prior to downstream applications.   Since the stem-
loop reverse transcription primers selectively target mature microRNAs, DNase treatment is not 
required (Mestdagh P. et al, 2008). Therefore, the experiments were carried out without using the 
DNase treatment and since then, consistently high RNA quality was obtained for LCM cells (RIN>6) 
and tissue sections (RIN>7). Alternatively, it would be interesting to compare the RNA quality using a 
different RNA extraction miRNeasy Mini Kit (QIAGEN), which includes a different on-column 
DNase treatment. 
 
4.3. RNA quality and yield impact and real time RT-qPCR microRNA 
analysis  
 For a sensitive and reliable quantitative measurement of microRNA expression real-time (qRT-
PCR) reaction was the method used in this study. High RNA integrity is critical for optimal qRT-PCR 
and micro-array experiments. In this study, higher RNA quality was obtained for tissue sections 
samples than for laser captured cells samples and decreased variability of the qRT-PCR results was 
observed increasing RNA quality.   
 Although RT-PCR has been reported showing high sensitivity, good reproducibility and a wide 
quantification range, several factors present in samples as well as exogenous contaminants might to 
inhibit the RT as well as the PCR (Fleige S. and Pfaffl M.W., 2006). For instance, the presence of cell 
constituents, high genomic DNA concentration, and DNA binding proteins are relevant factors 
(Wilson, 1997). The presence of inhibitors in total high RNA quality sample might reduce reaction 
efficiency (Bustin and Nolan, 2004; Wong and Medrano, 2005).Therefore, RNA extraction must be 
carefully performed to guarantee high RNA integrity and removal of contaminating nulceases, 
genomic DNA and RT or PCR inhibitors. The normalization by an internal reference microRNA 
reduces or even diminishes tissue derived effects on qRT-PCR results.   
 In the present study, since microRNAs expression was detectable with too high CT values (>35 
for laser captured cells and >30 for tissue sections samples) for reliable detection even of less 
abundantly expressed microRNAs, a pre-amplification step was included in the protocol after reverse 
transcription to ensure enough amount of template cDNA for downstream real-time PCR. For further 
data analysis, only those microRNAs with a Ct value below 35 should be taken into account since CT 
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values above 35, therefore, considered noise. By including pre-amplification of cDNA obtained from a 
starting amount of 1 ng of RNA, the CT values were decreased for both tissue sections and laser 
captured cells samples. In the present study, the use of stem-loop primer pool to perform RT reaction 
and preamplification step of cDNA, not only increased the cDNA template amount as well as ruled out 
the need for multiple separate RT reactions per sample which could increase the possibilty of cross 
contamination and was more time-consuming. 
 Previous studies reported the use of pre-amplification in combination with the stem-loop 
procedure (Tang F., 2006; Cogswell J.P. et al, 2008) and evaluated the effects of the pre-amplification 
step on the reliability and sensitivity of microRNA expression assessment (Mestdagh et al, 2008). 
Mestdagh et al, performed an analysis of the potential bias of a pre-amplification of the microRNA 
cDNA by direct comparison of microRNA expression profiles obtained with and without pre-
amplification. To this purpose, they studied the profile of 384 microRNAs in three different NB cancer 
cell lines using the Megaplex reverse transcription. For Megaplex RT without pre-amplification, 400 
ng of total RNA was used, whereas for pre-amplified samples, 1 and 10 ng of total RNA wer used. 
They demonstrated that the Megaplex stem-loop PCR procedure in combination with limited cycle 
pre-amplification is a powerful method for microRNA expression profiling using small amounts of 
RNA. 
 However, the use of a pre-amplification step may lead to changes of relative microRNA 
expression levels in the original cell population. Therefore, to validate pre-amplification step, different 
amounts of laser captured cells should be tested to confirm that they amplify at the same rate. 
Moreover, equal amplification efficiency and a high degree of amplification specificity is required to 
obtain an unbiased pre-amplification of the microRNA cDNA. Mestdagh et al have identified the RT 
reaction as a major factor contributing to the observed variation, particularly for the low abundant 
microRNAs, but a certain degree of variation was attributed to the pre-amplification reaction itself. 
Therefore, expression data for low abundant microRNAs generated performing Megaplex reverse 
transcription followed by pre-amplification should be carefully interpreted to ensure that microRNA 
quantification using the pre- amplification procedure results in relative microRNA expression levels 
that represent the real situation in the cell population. To this purpose, results should always be 
confirmed in independent experiments or biological replicates. Furthermore, one of the limitations of 
real-time PCR resides in being highly susceptible to human error: improper assay development, 
incorrect data analysis, or unwarranted conclusions.  
 Overall, despite introducing a preamplification step improved RT-qPCR results for tissue 
sections samples, for the laser captured cells, further optimization is needed to obtain successful qPCR 
results. Once optimized the real-time PCR,this technique can be use to obtain the microRNAs 
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expression data to validate and corroborate the results of printed microRNA arrays. 
 
4.4. Concluding remarks and Future Prospects  
 Laser capture Microdissection (LCM) is a major technological advance that enables study of 
motor neurons precisely isolated from their natural surrounding microenvironment in spinal cord 
tissue. However, it is challenging to obtain consistently high RNA quality and yield necessary for 
quantify microRNA expression from laser captured cells. 
 In this study, the protocol for laser capture Microdissection (LCM) of motor neurons from 
spinal cord tissue sections was successful optimized to obtain high RNA quality for use in Taqman 
rodent microRNA array and RT-qPCR validation.  
 The microRNA array results obtained in preliminary study showed subtler microRNA 
expression changes between SOD1
G93A
 mice and WT mice, than expected. These results were not 
considered reliable mainly since RNA was very degraded. In the present study, by introducing RNA 
inhibitor, high RNA quality was achieved. Therefore, this work provides a strong foundation for the 
microRNA array experiments, which will take place later in the year.  
 Microarray analysis of total RNA from SOD1
G93A
 compared to WT mice will be performed to 
determine the meaningful microRNA profile for motor neuron cells at a pre-symptomatic stage of 
ALS. Bioinformatics and statistics tools may be used to found at least one reliable candidate 
microRNA significantly changed in expression, that should be further validated using Taqman specific 
primers RT-qPCR. Once identified the microRNAs candidates to study in ALS disease context, 
computational and experimental approaches can be used to identify microRNA-regulated genes. From 
candidate microRNA gene target lists obtained we can focus attention on biologically significant 
target genes and pathological pathways to predict effects of microRNA deregulation in SOD1
G93A
 
mouse model of ALS.  
 MicroRNAs are crucial regulators of numerous cellular processes and their expression 
changes may reflect the ALS associated events at different time points; prior to disease onset, during 
the disease progression and death. Genetic mutations associated with familial ALS may be correlated 
with deregulated miRNAs that act upstream of pathology leading to impaired target pathways and 
pathways regulating expression of other microRNAs.  
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 However, the correlation between miRNA expression changes in SOD1
G93A
 mouse model and 
ALS pathology in humans should be carefully studied. Despite the mouse model of ALS used in this 
study replicates many of the clinical, molecular and cellular features including the selective 
vulnerability of motor neurons seen in the human disease, this model has also shown drawbacks. The 
biological function of most miRNAs is not fully understood and the total number of microRNA is 
likely not yet determined since over the last decade the list of miRNAs has greatly expanded. 
Moreover, it is estimated that only approximately 60% of human genes have conserved miRNA target 
sites in the mouse (R.C. Friedman et al, 2008; Griffiths-Jones S, 2008). Therefore, there is still 
substantial concern about the reliability of mouse model applications in studying the role of miRNAs 
in human ALS. Moreover, overexpressing human transgene SOD1G93A may lead to artefacts in 
mimic ALS pathological pathways since effects in mitochondrial loading were observed in previous 
studies (Bergemalm, D. et al, 2006). Furthermore, many therapeutic approaches based in study of 
SOD1
G93A
 ALS mouse model tested in ALS human patients have been so far unsuccessful (Benatar 
M., 2007,Van Den Bosch L, 2011). However, It was concluded that the majority of published positive 
neuroprotective effects were due to biological noise poor quality of preclinical study design, which 
might explain the failure of human therapeutic trials (Scott S. et al, 2008; Mead J.R. et al, 2011).  
 The optimization of the techniques described in this study may contribute to the role of 
microRNA to find miRNAs candidates, which are deregulated in early pathogenesis and may be 
involved in triggering the events that lead to disease progression to death, by affecting putative targets 
related to protein-degradation pathways and signalling pathways associated with cell, synapse function 
and neurodegeneration; rather than secondary consequence of cell injury and death in ALS.  
 Studies in human ALS patients are critical since the material can only be collected at the end 
stage of disease, so studies in mouse models allow to obtain material through the lifespan of the mice 
compared miRNAs expression levels according to the different timepoints of ALS. Alternatively to 
SOD1G93A mouse model, a more recent mouse model of ALS carrying the TDP-43 mutation can be 
used to hopefully obtain results more closely correlated with human ALS (Wegorzewska I. et al, 
2009).  To enhancing our understanding of the miRNAs regulating motor neurons functioning in 
normal and ALS states, these studies could be extended to motor neurons derived from induced 
pluripotent stem cells from skin biopsies taken from patients and controls. Furthermore, the expression 
of miRNAs and their putative targets could be assessed by qPCR and Western blotting and a full 
transcriptional profile associated with these mutations could be established. Moreover, by knockdown 
of target miRNAs, it would be possible to confirm that the pathological pathway changes associated 
with ALS associated mutations were dysregulated.  
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 Advances in understanding miRNAs in neurodegenation will require future research relying 
on adavanced and refined technologies, improved experimental animal models, the accessibility of 
patients-derived material and the embracement of new conceptual views on the patholophysiology of 
ALS. 
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Supplementary data 
Supplement  S1: TaqMan MicroRNA Arrays 
 
 
Table S1: Significantly dysregulated miRNAs ( ≥ 2-fold change) in SC tissue is SOD1 G93A compared 
to wt mice (n = 4). 2 ng of reserve-transcribed total RNA was pre-amplified for each sample using the 
Megaplex 
TM
 PreAmp Rodent primer pools A and B (Applied Biosystems). Real-time Megaplex 
TM
 
PCR reactions including the pre-amplified cDNA template and TaqMan Universal PCR Master Mix 
were loaded on to TaqMan Rodent MicroRNA Array cards were run on a 7900HT system (Applied 
Biosystems). 
 
 
 
 
 
Target Fold change 
p-value 
(<0.05) 
Regulation Mature sequence 
mmu-miR-34c   21.3 0.0366 up AGGCAGUGUAGUUAGCUGAUUGC 
mmu-miR-182   43.4 0.0402 up UUUGGCAAUGGUAGAACUCACACCG 
mmu-miR-31* - 24.7 0.0298 down AGGCAAGAUGCUGGCAUAGCUG 
mmu-let-7c-1*   4.1 0.0015 up UGAGGUAGUAGGUUGUAUGGUU 
mmu-miR-196c - 4.4 0.0382 down UAGGUAGUUUCGUGUUGUUGGG 
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